Antiviral Drugs - North America | Statista Market Forecast

The projected revenue in the Antiviral Drugs market in North America is set to reach US$31.73bn by 2024.
Looking ahead, the market is expected to demonstrate an annual growth rate of 1.37% from 2024 to 2029, resulting in a market volume of US$33.96bn by 2029.
In comparison to other countries, United States is forecast to generate the highest revenue, amounting to US$30.64bn in 2024.
The demand for antiviral drugs in North America has surged due to the increasing prevalence of viral infections.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

The demand for antiviral drugs in North America has been on the rise in recent years, driven by various factors such as the increasing prevalence of viral infections, growing awareness about the benefits of antiviral drugs, and advancements in drug development technologies.

Customer preferences: Customers in North America are increasingly seeking antiviral drugs that are effective against a broad range of viral infections and have fewer side effects. They also prefer drugs that can be administered orally and have shorter treatment durations. Additionally, there is a growing demand for antiviral drugs that can be used as prophylactics to prevent viral infections.

Trends in the market: One of the major trends in the North American antiviral drugs market is the increasing focus on developing drugs for emerging viral infections such as Zika, Ebola, and COVID-19. Another trend is the growing adoption of combination therapies that involve the use of multiple antiviral drugs to improve treatment outcomes. Additionally, there is a growing trend towards the development of antiviral drugs that target specific viral proteins or enzymes.

Local special circumstances: The North American market is characterized by a high level of competition among drug manufacturers, with several large multinational companies dominating the market. Additionally, the market is highly regulated, with strict approval processes and pricing regulations in place. There is also a growing trend towards the use of antiviral drugs in combination with other therapies such as immunotherapy and gene therapy.

Underlying macroeconomic factors: The North American antiviral drugs market is driven by various macroeconomic factors such as the increasing prevalence of viral infections, rising healthcare expenditure, and growing investment in drug development and research. Additionally, the market is influenced by demographic factors such as an aging population and increasing urbanization. The market is also impacted by geopolitical factors such as trade policies and regulations.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.